Difluoromethylornithine: The proof is in the polyamines

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC). They conclude that those treated with DFMO had a nonsignificant, persistent decrease in NMSC after completion of treatment and that treatment with DFMO did not result in late toxicity after the discontinuation of treatment. We review the data on DFMO as a chemopreventive agent for skin and other cancers, discuss the necessary qualities of a cancer chemopreventive agent, and reflect on the requirements for a well-conducted cancer chemoprevention study, including the rationale for long-term follow-up in cancer prevention studies.

Original languageEnglish (US)
Pages (from-to)1341-1344
Number of pages4
JournalCancer Prevention Research
Volume5
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Eflornithine
Polyamines
Skin Neoplasms
Neoplasms
Chemoprevention
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Difluoromethylornithine : The proof is in the polyamines. / Jeter, Joanne M; Alberts, David S.

In: Cancer Prevention Research, Vol. 5, No. 12, 12.2012, p. 1341-1344.

Research output: Contribution to journalArticle

@article{58007c55dc2a435e85899823ebcedb42,
title = "Difluoromethylornithine: The proof is in the polyamines",
abstract = "In this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC). They conclude that those treated with DFMO had a nonsignificant, persistent decrease in NMSC after completion of treatment and that treatment with DFMO did not result in late toxicity after the discontinuation of treatment. We review the data on DFMO as a chemopreventive agent for skin and other cancers, discuss the necessary qualities of a cancer chemopreventive agent, and reflect on the requirements for a well-conducted cancer chemoprevention study, including the rationale for long-term follow-up in cancer prevention studies.",
author = "Jeter, {Joanne M} and Alberts, {David S}",
year = "2012",
month = "12",
doi = "10.1158/1940-6207.CAPR-12-0429",
language = "English (US)",
volume = "5",
pages = "1341--1344",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Difluoromethylornithine

T2 - The proof is in the polyamines

AU - Jeter, Joanne M

AU - Alberts, David S

PY - 2012/12

Y1 - 2012/12

N2 - In this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC). They conclude that those treated with DFMO had a nonsignificant, persistent decrease in NMSC after completion of treatment and that treatment with DFMO did not result in late toxicity after the discontinuation of treatment. We review the data on DFMO as a chemopreventive agent for skin and other cancers, discuss the necessary qualities of a cancer chemopreventive agent, and reflect on the requirements for a well-conducted cancer chemoprevention study, including the rationale for long-term follow-up in cancer prevention studies.

AB - In this issue (beginning on page 1368), Kreul and colleagues report a retrospective review of long-term efficacy and toxicity for subjects participating in a phase III study of difluoromethylornithine (DFMO) for prevention of nonmelanoma skin cancer (NMSC). They conclude that those treated with DFMO had a nonsignificant, persistent decrease in NMSC after completion of treatment and that treatment with DFMO did not result in late toxicity after the discontinuation of treatment. We review the data on DFMO as a chemopreventive agent for skin and other cancers, discuss the necessary qualities of a cancer chemopreventive agent, and reflect on the requirements for a well-conducted cancer chemoprevention study, including the rationale for long-term follow-up in cancer prevention studies.

UR - http://www.scopus.com/inward/record.url?scp=84870675177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870675177&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-12-0429

DO - 10.1158/1940-6207.CAPR-12-0429

M3 - Article

C2 - 23221207

AN - SCOPUS:84870675177

VL - 5

SP - 1341

EP - 1344

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 12

ER -